🧠 Brainlab IPO: AI and Surgery Combination Goes Public with Growth Vision and Margins Over 25%

🔍 Brainlab doesn't just make tools. It creates the digital brain of the operating room that helps surgeons make decisions and perform precise surgery in real time.

📈 What attracts investors?

• High-margin revenue model - the software/hardware combination enables recurring revenue and strong cash flow
• Strong market position in neurosurgery and spinal surgery
• AI-first DNA: native capabilities in real surgery data processing
• Customer loyalty through solution complexity and surgeon training
• Clear growth strategy:
• • Expansion into orthopedics, sports medicine, cardiology
  • Expansion of sales network (including ambulatory surgery centers)
  • Strengthening of SaaS model

🧠 Who is Brainlab a good investment for?

✅ Yes, if:

• You believe in the future of software and AI in medicine
• you are looking for a growth medtech with a reasonable valuation
• you understand the risks of the regulatory environment and competition
• you want exposure to an innovative European title

❌ Think twice if:

• you are looking for dividend certainty
• you are averse to the risk/uncertainties of a new IPO
• you are expecting a short-term gain (first 6 months = confidence test)

🗣️ Investor Summary:

"Brainlab is not just another medtech - it's a software-defined approach to surgery. If it delivers on its promise of growth and expansion, it could become the Salesforce of surgical theatres."

"The European IPO scene may be asleep, but Brainlab is waking up with a clear vision. And with margins that even Big Tech would envy."